Dechert LLP

Dechert LLP is at the forefront of debt offerings by life sciences companies and permanent capital vehicles, including business development companies (BDCs). It also operates in multiple other sectors. In BDCs, the firm’s commitment to corporate and securities, securitisation and the Investment Company Act of 1940 expertise, has enabled it to standout in this area. The capital markets team primarily operates in middle market deals, though often ventures into the $1bn+ arena. Washington DC partner Harry Pangas heads the US capital markets group, which includes Boston-based co-head of the permanent capital practice, Thomas Friedmann. New York’s David Rosenthal is another key figure for life sciences sector offerings.